HRT is indicated for the treatment of moderate ▪ to severe vasomotor and urogenital symptoms associated with menopause. HRT is not recommended for primary prevention of ▪ disease because of increased risk of other adverse events. The use of HRT increases the risk of stroke, venous ▪ thromboembolism (VTE) and gall bladder disease and combined oestrogen progestogen therapy is also associated with...

728 The 2017 hormone therapy position statement of The North American Menopause Society This updated, evidence-based hormone therapy position statement of The North American Menopause Society analyzes the benefi ts and risks of the use of hormone therapy in an individual woman, including age at initiation or time since menopause onset, specifi c formulations or types of hormone therapy, duratio...

Introduction: Fulvestrant has demonstrated efficacy in hormone receptor positive (HR+) metastatic breast cancer (mBC), both first-and second-line settings. In clinical practice, however, fulvestrant been used as a later-line therapy. This study assessed the of women with mBC early-versus Methods: retrospective cohort Saskatchewan HR+ who received between 2003–2019. A multivariate Cox proportion...